Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Exploring Targeted and CAR T-Cell Therapies on the Horizon for MCL
Michael Wang, MD, discusses potential upcoming treatment options for patients with mantle cell lymphoma, including targeted therapies and chimeric antigen receptor T cells.
Building better CAR-T therapies
The success of chimeric antigen receptor T-cell (CAR-T) therapy has electrified the oncology field. Many specialists gush about its promise. But most people with cancers that the therapy could treat do not currently benefit from it.
Immuno-oncology drug development forges on despite COVID-19
Immunotherapy is now a mainstay of cancer treatment. Here, we provide our latest update on the global immuno-oncology (IO) drug pipeline, including comparisons with analogous analyses conducted in the previous 3 years.
Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large...
Cancer-associated venous thromboembolism (VTE) constitutes a major cause of morbidity and mortality in patients with hematologic malignancies.1 VTE can occur after chimeric antigen receptor (CAR) T-cell therapy, whereas coagulopathy in the form of low fibrinogen and bleeding can be complications of cytokine release syndrome (CRS).
Enhancing antitumor immunity through checkpoint blockade as a therapeutic strate...
The majority of historical therapies for managing T-cell lymphomas (TCLs) have consisted of T-cell–depleting strategies. Unfortunately, these forms of therapies can hamper the ability to mount effective antitumor immune responses. Recently, the use of checkpoint inhibitors has revolutionized the therapy of solid and hematologic malignancies.
Save the Date for the 3rd European CAR T-cell Meeting: February 4-6, 2021
EHA and EBMT are excited to announce the 3rd edition of the jointly organized European CAR T-cell Meeting. This meeting will be held virtually, from February 4-6, 2021, ensuring everyone can safely attend and learn about the new developments in the CAR-T arena.
A DNA nanodevice-based vaccine for cancer immunotherapy
A structurally well defined DNA nanodevice vaccine generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure that can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity.
Limited evidence of tumour mutational burden as a biomarker of response to immun...
Several studies have suggested that Tumor Mutational Burden (TMB) correlates with patient response to ICB treatments 2–6, likely due to immunogenic neoantigens generated by novel mutations accumulated during cancer progression.
Metabolic engineering against the arginine microenvironment enhances CAR-T cell ...
Hematological and solid cancers catabolize the semiessential amino acid arginine to drive cell proliferation. However, the resulting low arginine microenvironment also impairs chimeric antigen receptor T cells (CAR-T) cell proliferation, limiting their efficacy in clinical trials against hematological and solid malignancies.
Human immunology and immunotherapy: main achievements and challenges
The development of different types of immunotherapies, including vaccines (prophylactic and therapeutic), and the use of pathogens, monoclonal antibodies, recombinant proteins, cytokines, and cellular immunotherapies, are changing the way in which we approach many diseases, especially cancer.